|
|
Volumn 63, Issue 9, 2014, Pages 942-943
|
|
Limits of mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL MARKER;
MESSENGER RNA;
PHOSPHOLIPASE A2 GROUP II;
PHOSPHOLIPASE A2 IIA;
UNCLASSIFIED DRUG;
VARESPLADIB;
ATORVASTATIN;
PHOSPHOLIPASE A2;
PHOSPHOLIPASE A2 GROUP IIA;
VARESPLADIB METHYL;
ACUTE CORONARY SYNDROME;
ALLELE;
CARDIOVASCULAR DISEASE;
ENZYME ACTIVITY;
ENZYME INHIBITION;
ENZYME RELEASE;
GENETIC VARIABILITY;
HEART PROTECTION;
HUMAN;
ISCHEMIC HEART DISEASE;
LETTER;
OBSERVATIONAL STUDY;
PHARMACOGENETICS;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PROTEIN TARGETING;
SIGNAL TRANSDUCTION;
CLINICAL TRIAL (TOPIC);
DRUG EFFICACY;
DRUG POTENCY;
MENDELIAN RANDOMIZATION ANALYSIS;
CARDIOVASCULAR DISEASES;
DNA;
GENE EXPRESSION REGULATION;
HUMANS;
MENDELIAN RANDOMIZATION ANALYSIS;
PHOSPHOLIPASES A2, SECRETORY;
|
|
EID: 84895552272
PISSN: 07351097
EISSN: 15583597
Source Type: Journal
DOI: 10.1016/j.jacc.2013.09.074 Document Type: Letter |
|
Times cited : (2)
|
|
References (6)
|
